Financial Performance - The company's revenue for Q3 2022 reached ¥526,669,326.65, representing a year-on-year increase of 23.63%[3] - Net profit attributable to shareholders for Q3 2022 was ¥246,969,740.89, up 32.07% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥225,401,612.58, reflecting a growth of 29.24% year-on-year[3] - Total operating revenue for Q3 2022 reached RMB 1,211,130,217.72, an increase of 21.5% compared to RMB 996,129,093.67 in the same period last year[24] - The net profit for Q3 2022 was CNY 566,280,127.21, an increase of 18.87% compared to CNY 476,342,514.11 in Q3 2021[26] - Operating profit reached CNY 650,157,627.95, up from CNY 554,639,148.42 in the same period last year, reflecting a growth of 17.19%[26] - The total comprehensive income for the period was CNY 566,280,127.21, compared to CNY 476,342,514.11 in Q3 2021, showing an increase of 18.87%[28] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥5,064,495,868.77, a significant increase of 70.38% from the end of the previous year[4] - The equity attributable to shareholders at the end of Q3 2022 was ¥4,104,107,634.93, marking an 85.22% increase compared to the end of the previous year[4] - Total assets as of September 30, 2022, were RMB 5,064,495,868.77, a substantial rise from RMB 2,972,426,471.10 at the end of the previous year[23] - The company's total liabilities increased to RMB 589,305,827.63 from RMB 436,351,201.51, marking a year-over-year growth of 35%[22] Cash Flow - The company reported a net cash flow from operating activities of ¥556,837,279.19 for the year-to-date, which is a 12.23% increase year-on-year[3] - Cash flow from operating activities was CNY 556,837,279.19, compared to CNY 496,148,435.26 in the previous year, indicating a growth of 12.19%[29] - The company reported a net cash outflow from investment activities of -¥1,107,394,913.11, a decrease of 498.82% compared to the previous period[13] - The company’s investment activities resulted in a net cash outflow of CNY 1,107,394,913.11, compared to a net inflow of CNY 277,669,907.92 in the previous year[30] - Net cash flow from financing activities rose significantly by 833.36% to ¥1,333,313,011.24, mainly from issuing shares to specific investors[15] - The company’s financing activities generated a net cash inflow of CNY 1,333,313,011.24, compared to a net cash outflow of CNY 181,809,659.91 in Q3 2021[30] Operational Efficiency - The company’s gross profit margin improved due to enhanced sales and cost control measures, contributing to the increase in net profit for Q3 2022[9] - Total operating costs for Q3 2022 were RMB 606,461,697.71, up from RMB 507,492,351.31, reflecting a year-over-year increase of 19.5%[24] - Research and development expenses increased to CNY 25,223,950.66, a rise of 22.06% from CNY 20,560,255.26 in Q3 2021[26] Market Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[20] - The company is actively exploring opportunities for mergers and acquisitions to enhance its competitive position in the market[20] Shareholder Information - The number of shares held by the top 10 shareholders indicates strong institutional support, with the largest shareholder holding 36,342,885 shares[18] Other Financial Metrics - Cash and cash equivalents increased by 119.42% to ¥1,438,726,646.80 compared to ¥655,691,465.82 at the end of 2021[10] - Trade receivables rose by 46.61% to ¥228,352,167.38, attributed to higher sales volume in Q3[10] - Other current assets surged by 253.26% to ¥802,866,195.60, mainly due to an increase in principal-protected fixed-income financial products[11] - Financial expenses decreased by 224.30% to -¥4,885,745.97, primarily due to increased interest income from bank deposits[12] - Investment income fell by 45.51% to ¥33,371,713.66, due to reduced gains from the transfer of subsidiary equity[12] - Cash and cash equivalents as of September 30, 2022, amounted to RMB 1,438,726,646.80, compared to RMB 655,691,465.82 at the beginning of the year, indicating a significant increase of 118.5%[20] - Cash and cash equivalents at the end of the period totaled CNY 1,437,996,509.81, up from CNY 918,268,612.21 at the end of Q3 2021, representing a growth of 56.67%[30] - The capital reserve increased dramatically by 3083.16% to ¥1,555,821,608.75, reflecting the premium from shares issued to specific investors[11]

Revenue and Profitability - The company reported a significant reliance on orthokeratology lenses and related products, which currently account for the majority of its sales revenue[5]. - The company's operating revenue for the first half of 2022 was RMB 684,460,891.07, representing a 20.05% increase compared to RMB 570,137,743.19 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was RMB 258,271,355.90, a slight increase of 0.90% from RMB 255,968,022.93 year-on-year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 238,754,124.12, reflecting a 13.16% increase from RMB 210,997,096.28 in the previous year[23]. - The main driver for revenue growth was the increasing application of the company's core product, orthokeratology lenses, despite significant impacts from COVID-19 restrictions[31]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-on-year growth of 20%[168]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[168]. - The company anticipates a positive cash flow of 200 million RMB by the end of 2022, supporting its growth initiatives and investments[168]. Market Expansion and Product Development - The company is expanding its business into optometry services and comprehensive optometry products to diversify its product structure[6]. - The company is developing its own lens materials, which have passed national performance testing, to mitigate risks associated with imported raw materials[5]. - The company has expanded its production capacity with the addition of two new production lines for lens manufacturing[35]. - The company is investing 100 million RMB in R&D for new technologies aimed at improving product efficiency and user experience[168]. - New product development includes the launch of a next-generation smart lens, expected to contribute an additional 200 million RMB in revenue by Q4 2022[168]. - The company is actively pursuing partnerships and acquisitions to strengthen its market position in the healthcare industry[146]. Financial Performance and Assets - The total assets at the end of the reporting period were RMB 4,662,178,663.65, marking a 56.85% increase from RMB 2,972,426,471.10 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company increased by 74.19% to RMB 3,859,696,820.41 from RMB 2,215,832,945.45 at the end of the previous year[23]. - Cash and cash equivalents increased to RMB 2,059,751,753, representing 44.18% of total assets, up from 22.06% in the previous year, due to funds received from issuing shares[54]. - The company reported a significant increase in long-term equity investments, indicating a strategic focus on enhancing control and influence over key subsidiaries[182]. - The company’s total assets amounted to RMB 4,131,562,310.76, compared to RMB 2,460,936,411.05 in the previous year, reflecting a strong asset growth[117]. Risk Management and Legal Considerations - The company faces risks related to the concentration of sales in the East China region, which remains significantly higher than other regions[6]. - The company acknowledges potential legal risks associated with the long-term use of its medical optical devices[5]. - The company is actively managing risks related to increased competition from both domestic and international brands in the orthokeratology lens market[8]. - The company emphasizes a "safety first" approach in its risk management framework, focusing on product quality and user safety[47]. Research and Development - The company emphasizes a strong R&D advantage with a dedicated team that has over 20 years of experience in the rigid contact lens field, supporting continuous innovation and market leadership[40]. - Research and development investment increased by 27.91% to ¥16,992,355.64, compared to ¥13,284,158.18 in the previous year[50]. - The company has obtained 3 invention patents, 1 utility model patent, and 1 design patent related to medical devices during the reporting period[35]. Subsidiaries and Ownership Structure - The company holds a 100% stake in 18 subsidiaries, indicating strong control over its operations[146]. - The company has established a significant number of subsidiaries focused on eye care and medical devices, reflecting its commitment to this sector[147]. - The company has a 51% to 66.25% stake in several subsidiaries, suggesting a diversified investment strategy in the healthcare sector[146]. - The company is expanding its market presence with multiple subsidiaries across various regions, including Qingdao and Yantai[146]. Shareholder and Governance - The company has not declared any cash dividends or stock bonuses for the reporting period[9]. - The company held its annual general meeting on April 20, 2022, with a participation rate of 57.13%[83]. - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[84]. - The total number of shares increased from 850,508,170 to 894,831,756, with an increase of 44,323,586 shares due to a specific issuance[101]. Compliance and Reporting - The financial report for the first half of 2022 was not audited[112]. - The company adheres to the Chinese accounting standards, ensuring that its financial statements accurately reflect its financial position and operational results[159]. - The company has implemented a unified accounting policy for mergers and acquisitions, ensuring consistency in financial reporting across its subsidiaries[160]. Cash Flow and Financing Activities - The net cash flow from operating activities was RMB 266,346,288.44, down by 3.55% from RMB 276,162,123.91 in the same period last year[23]. - The net cash flow from financing activities surged by 934.40% to ¥1,352,905,139.14, primarily due to funds received from issuing shares to specific investors[50]. - Cash inflow from financing activities amounted to ¥1,544,799,788.29, with a net cash flow of ¥1,417,216,654.81, significantly improving from a negative cash flow of -¥130,820,812.94 in the previous year[127].

Financial Performance - The company's revenue for Q1 2022 was ¥371,150,930.09, representing a 29.35% increase compared to ¥286,936,799.16 in Q1 2021[3] - Net profit attributable to shareholders for Q1 2022 was ¥148,100,239.31, a 7.24% increase from ¥138,104,771.92 in the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥137,680,611.82, up 28.66% from ¥107,012,556.45 in Q1 2021[3] - Operating revenue for the current period reached ¥371,150,930.09, an increase of 29.35% compared to the previous period's ¥286,936,799.16[11] - The total revenue for the first quarter of 2022 was approximately 185.84 million CNY, an increase from 167.73 million CNY in the same period last year, representing an increase of about 7.5%[24] - The net profit for the first quarter of 2022 was approximately 163.41 million CNY, compared to 146.94 million CNY in the previous year, reflecting a growth of around 11.2%[24] - Basic earnings per share for the first quarter of 2022 were 0.1744 CNY, up from 0.1629 CNY in the same quarter of the previous year, indicating an increase of approximately 9.2%[25] - The total comprehensive income for the first quarter of 2022 was approximately 163.41 million CNY, compared to 146.94 million CNY in the same period last year, marking an increase of about 11.2%[25] Cash Flow and Investments - The company's cash flow from operating activities for Q1 2022 was ¥158,750,502.59, a slight increase of 0.65% from ¥157,725,436.22 in Q1 2021[3] - Net cash flow from operating activities was ¥158,750,502.59, a slight increase of 0.65% compared to the previous period[12] - Investment activities resulted in a net cash outflow of ¥58,322,480.11, improving from a net outflow of ¥65,086,963.22 in the previous period[12] - Financing activities generated a net cash inflow of ¥17,017,312.57, a significant increase of 656.88% compared to the previous period[12] - The net cash flow from investment activities was -58,322,480.11 CNY, an improvement from -65,086,963.22 CNY in the previous year[27] - Cash inflow from financing activities totaled 51,212,679.20 CNY, significantly higher than 5,332,814.50 CNY in the same period last year[27] - The net cash flow from financing activities was 17,017,312.57 CNY, compared to 2,248,340.18 CNY in the previous year[27] - The company received 48,790,375.20 CNY from investment, a substantial increase from 4,884,815.00 CNY in the previous year[27] Assets and Liabilities - Total assets as of March 31, 2022, were ¥3,184,618,997.44, reflecting a 7.14% increase from ¥2,972,426,471.10 at the end of the previous year[4] - The total liabilities as of March 31, 2022, were CNY 467,767,304.74, compared to CNY 436,351,201.51 at the start of the year[22] - The cash and cash equivalents at the end of the first quarter were CNY 773,129,800.87, up from CNY 655,691,465.82 at the beginning of the year[20] - The inventory level increased to CNY 113,088,305.11 from CNY 105,960,111.58 at the start of the year, indicating a growth of 6.3%[20] - The company reported a significant increase in accounts receivable, which rose to CNY 181,085,437.92 from CNY 155,759,640.48, reflecting a growth of 16.3%[20] Shareholder Information - The company’s major shareholder, Nanjing Otao Information Technology Co., Ltd., holds 14.41% of shares, amounting to 122,790,521 shares[13] - The total number of ordinary shareholders at the end of the reporting period was 64,899[13] Future Plans - The company plans to continue expanding its market presence and investing in new product development[12] - The company has plans for future expansion and product development, although specific details were not provided in the financial report[18] Other Financial Metrics - The weighted average return on net assets for Q1 2022 was 6.46%, down from 7.59% in the same period last year[4] - The company adjusted its idle fund investment structure, resulting in a decrease of approximately ¥4.15 million in investment income compared to the previous year[7] - Financial expenses decreased by 97.18% to ¥57,276.13, attributed to increased interest income from bank deposits[11] - The company reported a 331.89% increase in other income, totaling ¥2,225,743.75, primarily due to increased government subsidies[11] - The company reported investment income of approximately 7.20 million CNY, a significant decrease from 32.77 million CNY in the previous year, indicating a decline of about 78%[24] - The operating profit for the first quarter of 2022 was approximately 185.69 million CNY, compared to 167.59 million CNY in the same period last year, reflecting an increase of about 10.8%[24] Audit and Reporting - The company did not conduct an audit for the first quarter report[28] - The report was officially announced by the board of directors on April 27, 2022[29]